Skip to main content
Equibles
OCGN logo

OCGN · Ocugen, Inc. · Documents

Track OCGN — free

Use OCGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.81 -0.01 (-0.80%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“After evaluating these conditions and management’s plans, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 4, 2026
Market Cap
$294.01M
Shares
339.31M
Volume · Nov 5 7.15M Avg daily vol (3M) 6.56M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $4.41M up 8.8% 10-K filed Mar 4, 2026 Quarterly report New FY2026 Q3 Revenue $1.95M up 11.4% 10-Q filed Nov 4, 2026 Latest results New Financial results 8-K filed Nov 4, 2026 Earnings call New Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Substantial doubt raised over one-year going concern

Ocugen cited substantial doubt about continuing as a going concern within one year after issuance, citing recurring operating losses, negative cash flow and financing uncertainties. Cash and short-term investments totaled $84.3 million as of September 30, 2026.

Revenue $1.95M ▲ 11.4% Net loss $3.6M Diluted EPS -$0.01
Read from the MD&A section
3 source passages
Ocugen’s modifier gene therapy platform underpins all of our late-stage clinical development programs and has the potential to address significant unmet medical needs across large global patient populations through a gene-agnostic approach. After evaluating these conditions and management’s plans, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued. As of September 30, 2026, we had an accumulated deficit of $455.7 million and cash and cash equivalents and short-term investments totaling $84.3 million. Open the document at this passage
Oct 15
Current report 8-K
Regulation FD disclosure

Ocugen targets three BLAs by 2028: OCU400 in retinitis pigmentosa, OCU410ST in Stargardt disease and OCU410 in geographic atrophy. OCU400 received provisional Bahamas approval; OCU410’s Phase 3 began in 3Q 2026, and OCU410ST enrollment is complete.

Oct 6
Current report 8-K Events of Oct 5
Shareholder vote results

Ocugen reconvened its Special Meeting on October 5, 2026 and adjourned again solely to consider a proposal to increase authorized common shares by 250,000,000; the reconvened meeting is scheduled for October 26, 2026 at 8:00 a.m., Eastern Time.

Sep 23
Current report 8-K Events of Sep 21
Shareholder vote results

Ocugen stockholders approved adjourning the special meeting solely to reconsider increasing authorized common stock by 250,000,000 shares, with voting on that proposal rescheduled for October 5, 2026, at 8:00 a.m., Eastern Time.

Aug 6
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.49M ▲ 8.4% Net loss $24.88M Diluted EPS -$0.07
Jul 30
Proxy statement DEF 14A Meeting Sep 21, 2026
Proxy statement AI summary on its way
Jul 20
Proxy statement PRE 14A Meeting Sep 21, 2026
Proxy statement AI summary on its way
Jul 13
Current report 8-K
Other events AI summary on its way
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.53M ▲ 3.5% Net loss $19.18M Diluted EPS -$0.06
Apr 28
Proxy statement DEF 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Apr 17
Proxy statement PRE 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Mar 20
Current report 8-K Events of Mar 12
Other events AI summary on its way
Mar 4
Current report 8-K
Other events AI summary on its way
Mar 4
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $4.41M ▲ 8.8% Net loss $67.85M
Jan 15
Current report 8-K
Other events AI summary on its way
2025
Showing 1–50 of 305 documents
Key facts CIK 1372299 CUSIP 67577C105 13F (30d) 57 filings 44 filers Visit website Investor relations